Has closed According to a release.

USD Underwriter exercises possibility of additional common shares[ Professional Services Close – Up] BuyBofA Merrill Lynch acted as sole book-running managers for the offering.Has closed According to a release, the issue of additional shares, and all shares were sold by MAP Pharmaceuticals. The total gross proceeds were approximately $ 59, and the total net proceeds of approximately U.S. $ 56, net of underwriting discounts and commissions..

MAP Pharmaceuticals is a biopharmaceutical company focuses on addressing the development and commercialization of novel therapies to patients’ needs in neurology focused.MAP Pharmaceuticals intends to use the proceeds from this offering for general corporate purposes and commercialization efforts for LEVADEX, orally inhaled orally inhaled investigational drug for the acute treatment of migraine. Source: St.Yaron Almagor has, Jesselson cardiac center, Department of Cardiology, Shaare Zedek Medical Centre, Jerusalem, reported target lesion revascularization target lesion revascularization from zero %, MACE rate of zero per cent and one goal revascularization by eight %. – Commenting on these Results The, Dr. Almagor has said, If for use historical data from using the use of bare metal stents, these results suggest that the CYPHER A stent had outstanding clinical resources in treating of these highly ambitious nature of blockade. Stenosis.. SICTO surveyThe findings of the SICTO, a 25 – patient feasibility studies the CYPHER stent in treatment of CTO – defining chronic total occlusion was very encouraging.